Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash from Financing Activities (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Cash from Financing Activities data on record, last reported at $13.6 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 65.4% year-over-year to $13.6 million; the TTM value through Dec 2025 reached $1.4 million, down 96.17%, while the annual FY2025 figure was $1.4 million, 96.17% down from the prior year.
  • Cash from Financing Activities reached $13.6 million in Q4 2025 per VRCA's latest filing, up from -$4.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $44.0 million in Q3 2023 and bottomed at -$16.9 million in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $6.9 million, with a median of -$18000.0 recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: plummeted 39288.37% in 2022, then skyrocketed 168322.22% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$3000.0 in 2021, then tumbled by 561600.0% to -$16.9 million in 2022, then soared by 99.84% to -$27000.0 in 2023, then surged by 146122.22% to $39.4 million in 2024, then plummeted by 65.4% to $13.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $13.6 million in Q4 2025, -$4.0 million in Q3 2025, and -$4.2 million in Q2 2025.